Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

41. HIV infection and AIDS: Scenario: Established HIV infection

HIV infection and AIDS: Scenario: Established HIV infection Scenario: Established HIV infection | Management | HIV infection and AIDS | CKS | NICE Search CKS… Menu Scenario: Established HIV infection HIV infection and AIDS: Scenario: Established HIV infection Last revised in October 2018 Scenario: Established HIV infection From birth onwards. Review in primary care Monitoring of HIV infection will be done in specialist clinics using the CD4 count and viral load — see the section (...) on for additional information. People with HIV attending primary care may require: Advice about . Information on . Information on . Management for if needed. Management for HIV-related problems if needed. See the for more information. Be aware of potential problems with drug interactions — (ART) can have serious interactions with many other drugs, dietary substances, herbal remedies, and recreational drugs. To minimize the risk of drug interactions: Take a detailed medication history including over-the-counter

2020 NICE Clinical Knowledge Summaries

42. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

limited to English articles published since 2015. Reference lists of identified articles were also searched. The search yielded 1,343 references from which 28 were included. Reference list Newman DR, Rahman MM, Brantley A, Peterman TA. Rates of new human immunodeficiency virus (HIV) diagnoses after reported sexually transmitted infection in women in Louisiana, 2000–2015: Implications for HIV prevention. Clinical Infectious Diseases. 2019. Peterman TA, Newman DR, Maddox L, Schmitt K, Shiver S. Risk (...) . 1999;20(3):295–9. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study. American Journal of Epidemiology. 1997;146(4):350–7. Calabrese SK, Willie TC, Galvao RW, Tekeste M, Dovidio JF, Safon CB, et al. Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. Journal of Acquired Immune Deficiency Syndromes

2020 Ontario HIV Treatment Network

43. Invasive Nontypeable Haemophilus influenzae Infection Among Adults With HIV in Metropolitan Atlanta, Georgia, 2008-2018. Full Text available with Trip Pro

Invasive Nontypeable Haemophilus influenzae Infection Among Adults With HIV in Metropolitan Atlanta, Georgia, 2008-2018. Invasive nontypeable Haemophilus influenzae (NTHi) infection among adults is typically associated with bacteremic pneumonia. Nontypeable H influenzae is genetically diverse and clusters of infection are uncommon.To evaluate an increase in invasive NTHi infection from 2017-2018 among HIV-infected men who have sex with men in metropolitan Atlanta, Georgia.A population-based (...) surveillance study with a cohort substudy and descriptive epidemiological analysis identified adults aged 18 years or older with invasive NTHi infection (isolation of NTHi from a normally sterile site) between January 1, 2008, and December 31, 2018 (final date of follow-up).Time period, HIV status, and genetic relatedness (ie, cluster status) of available NTHi isolates.The primary outcome was incidence of invasive NTHi infection (from 2008-2016 and 2017-2018) among persons with HIV and compared with NTHi

2019 JAMA

44. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Pathophysiology in HIV: Metabolic Contributors HIV infection is associated with metabolic complications, including dyslipidemia, insulin resistance, and body composition changes, which can contribute to CVD. Initially, dyslipidemia in HIV was characterized by increased triglyceride levels, thought to be related to immunodeficiency in the pre-ART era. Later, specific ART medications, including several protease inhibitors (PIs) and efavirenz, a non–nucleoside reverse transcriptase inhibitor (NRTI), were (...) Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May

2019 American Heart Association

45. Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women

Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women (current immunosuppressants are listed in Table 2). Women with RA and IBD not on immunosuppressants and women with DM were considered at no increased risk compared with the general population. Screening recommendations based on these risks are summarizedinTable3. REFERENCES 1. GrulichAE,vanLeeuwenMT,FalsterMO,etal.Incidence ofcancersin peoplewithHIV/AIDScomparedwithimmunosuppressedtransplant recipients

2019 American Society for Clinical Pathology

46. HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing

. Human immunodeficiency virus testing practices and interest in self-testing options among young, Black men who have sex with men in North Carolina. Sexually Transmitted Diseases. 2016;43(9):587–93. Rosales-Statkus ME, de la Fuente L, Fernandez-Balbuena S, Figueroa C, Fernandez-Lopez L, Hoyos J, et al. Approval and potential use of over-the-counter HIV self-tests: The opinion of participants in a street based HIV rapid testing program in Spain. AIDS & Behavior. 2015;19(3):472–84. Sharma A, Sullivan (...) and bisexual men. AIDS & Behavior. 2014;18(12):2485–95. Udeagu CN, Shah S, Molochevski M. Men who have sex with men seek timely human immunodeficiency virus confirmation and care after rapid human immunodeficiency virus self-test: Data from partner services program, New York City. Sexually Transmitted Diseases. 2017;44(10):608–12. Ricca AV, Hall EW, Khosropour CM, Sullivan PS. Factors associated with returning at-home specimen collection kits for HIV testing among internet-using men who have sex with men

2019 Ontario HIV Treatment Network

47. Doravirine for the treatment of HIV-1 in adults

between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities Plain Language Summary About HIV-1 Human immunodeficiency virus (HIV) is a virus that damages a type of white blood cell in the immune system called a CD4 cell. Damaging CD4 cells weakens the body’s ability to fight off infection and disease, leaving people with HIV vulnerable to opportunistic infection. In some cases, this can lead (...) (lamivudine and tenofovir disoproxil). What we have decided NHS England has carefully reviewed the evidence prepared by NICE on treating HIV- 1 with doravirine. We have concluded that there is enough evidence to consider making the treatment available. 1 Introduction Human immunodeficiency virus type 1 (HIV-1) is a virus that damages the CD4 cells of the immune system, leaving the body less able to fight off infection and disease. In some cases the damage caused to the immune system by HIV leads

2019 NHS England

48. Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection

Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1} {1} {1} | | > > > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Dolutegravir (...) + rilpivirine (Juluca°) dual therapy in HIV infection FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options? Full review (3 pages) available for download by subscribers. Prescrire's rating NOTHING NEW In patients who have an undetectable viral load

2019 Prescrire

49. Unmet needs of Indigenous peoples living with HIV

Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV , , , , , , , , , Questions What are the unmet needs of Indigenous peoples living with HIV? What interventions, strategies, and programs have been used to address these needs? Key take-home messages In 2016, First Nations, Métis (...) , and Inuit peoples accounted for 4.9% of the Canadian population but represented 11.3% of all new HIV infections (1). When considering Indigenous health, conventional approaches to HIV and other communicable diseases are insufficient (2). Considerable disconnect exists between the priorities of the HIV care cascade and the experiences of Indigenous peoples living with HIV (3). The lack of coordination between mainstream HIV biomedical approaches and Indigenous worldviews appears to contribute to poor

2019 Ontario HIV Treatment Network

50. Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya Full Text available with Trip Pro

Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya Timely diagnosis of infant HIV infection is essential for antiretroviral therapy (ART) initiation. In a randomized controlled trial, we found the Texting Improves Testing (TextIT) intervention (a theory-based text messaging system) to be efficacious for improving infant HIV testing rates and maternal retention in prevention (...) of mother-to-child HIV transmission (PMTCT) programs. Using an implementation science approach, we aimed to evaluate real-world effectiveness of the intervention.In a pragmatic, cluster-randomized, stepped-wedge trial with 2 time periods of observation, we randomly allocated 10 clinics to begin implementing the intervention immediately and 10 clinics to begin implementing 6 months later. To approximate real-world conditions, inclusion criteria were broad. Women at clinics implementing the intervention

2019 EvidenceUpdates

51. Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. The World Health Organization recommends cryotherapy or loop electrosurgical excision procedure (LEEP) for histologically confirmed cervical intraepithelial neoplasia (CIN) grade 2 or higher regardless of HIV status. Cryotherapy is more feasible in resource-limited settings but may be less effective for women (...) living with HIV.To evaluate whether cryotherapy or LEEP is a more effective treatment for high-grade cervical lesions among women with HIV.Single-center randomized trial conducted among women with HIV and CIN grade 2 or 3. From June 2011 to September 2016, women with HIV in Kenya underwent cervical screening with Papanicolaou testing and confirmatory biopsy. The final date on which a study procedure was administered was September 7, 2016.Women with HIV infection and CIN grade 2 or 3 were randomized 1

2019 JAMA

52. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Full Text available with Trip Pro

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. The lateral flow urine lipoarabinomannan (LF-LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active tuberculosis in HIV-positive people with severe HIV disease. This review update asks the question, "does new evidence justify the use of LF-LAM in a broader group of people?", and is part of the WHO process for updating guidance (...) on the use of LF-LAM.To assess the accuracy of LF-LAM for the diagnosis of active tuberculosis among HIV-positive adults with signs and symptoms of tuberculosis (symptomatic participants) and among HIV-positive adults irrespective of signs and symptoms of tuberculosis (unselected participants not assessed for tuberculosis signs and symptoms).The proposed role for LF-LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis.We searched the Cochrane Infectious

2019 Cochrane

53. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. (Abstract)

Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown.In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during

2019 NEJM

54. Dovato - dolutegravir / lamivudine - HIV-1 infection

Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. Submission Type: New Project Status: Active Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: September 30, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH (...) Dovato - dolutegravir / lamivudine - HIV-1 infection dolutegravir / lamivudine | CADTH.ca Find the information you need dolutegravir / lamivudine dolutegravir / lamivudine Last Updated: October 3, 2019 Result type: Reports Project Number: SR0601-000 Product Line: Generic Name: dolutegravir / lamivudine Brand Name: Dovato Manufacturer: ViiV Healthcare Indications: HIV-1 infection Manufacturer Requested Reimbursement Criteria 1 : Indicated as a complete regimen for the treatment of Human

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

55. Ibalizumab (Trogarzo) - HIV-1

in the EU What is Trogarzo and what is it used for? Trogarzo is a medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Trogarzo is given with other HIV medicines when none of the standard combinations work to control the infection because the virus is resistant to them (multi-drug resistant HIV). Trogarzo contains the active substance ibalizumab. How is Trogarzo used? The medicine can only be obtained (...) should receive appropriate treatment. For more information about using Trogarzo, see the package leaflet or contact your doctor or pharmacist. How does Trogarzo work? The active substance in Trogarzo, ibalizumab, is a monoclonal antibody (a type of protein) designed to attach to CD4, a receptor (target) found on the surface of immune cells called T cells. T cells are the main target of the HIV virus, which it uses as a host to reproduce. By attaching to CD4, ibalizumab prevents the virus from

2019 European Medicines Agency - EPARs

56. The risk of coercion in the context of HIV self-testing

care, and protection from abuse (2–4). More research is needed on unintended consequences of self-testing in situations where testing is coercive and puts individuals at risk for violence if they refuse (5). The issue and why it’s important There are ethical and human rights concerns with respect to whether HIV self-testing (also known as home-testing or home-based HIV testing) could be used in coercive ways that are harmful to vulnerable people (6). Two areas of particular concern are abusive (...) the test (e.g., losing their job, breaking up a relationship, and not having sex) (7). Alais and Venter (2014) provide their views on ethical, legal and human rights concerns raised by licensing HIV self-testing for private use and argue that HIV self-home tests are not likely to be harmful in a way that justifies restricting people’s access to them, and have plausible benefits (6). At the same time, it is important that reasonably robust protections are in place to protect against coerced testing

2019 Ontario HIV Treatment Network

57. Sexual and reproductive health and HIV: applying All Our Health

Sexual and reproductive health and HIV: applying All Our Health Sexual and reproductive health and HIV: applying All Our Health - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Sexual and reproductive health (...) and HIV: applying All Our Health Evidence and guidance on improving sexual health in communities with contraception, HIV and STI testing and easy access to advice. Published 1 April 2015 Last updated 17 September 2019 — From: Documents HTML Details Examples to inform healthcare professionals and maximise their contribution to health protection by improving sexual health outcomes. Published 1 April 2015 Last updated 17 September 2019 17 September 2019 Updated information on sexual and reproductive

2019 Public Health England

58. Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076) Available information for Tivicay - Submission control number 207076 - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Available information for Tivicay - Submission control number 207076 From Content and search results on this site are in the language provided by the manufacturer. Access and use of clinical information is governed by the . Submission information Submission control

2019 Health Canada - drugs and medical devices

59. Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

60. Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V

of differentiation 4 DOR doravirine EFV efavirenz G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIV human immunodeficiency virus IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) NNRTI non-nucleoside reverse transcriptase inhibitors NRTI nucleoside/nucleotide reverse transcriptase inhibitors RCT randomized controlled trial RNA ribonucleic acid SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) TDF tenofovir (...) combination doravirine (DOR)/lamivudine (3TC)/tenofovir disoproxil fumarate (TDF) (DOR/3TC/TDF). The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as the “company”). The dossier was sent to IQWiG on 14 January 2019. Research question The aim of this report is to assess the added benefit of DOR/3TC/TDF in comparison with the appropriate comparator therapy (ACT) in adults infected with human immunodeficiency virus type 1 (HIV-1). The HI viruses must

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)